parisons between weights on admission and weights by day 3 showed that a larger proportion of children in the loperamide groups gained weight than in the placebo group. No serious side effects of loperamide were observed, but the drug was withdrawn in one infant because of mild abdominal distention.
cause the patient was clearly the victim of several clinical and diagnostic misadventures and should have had a parathyroid exploration. With this exception our patients with severe hyperparathyroidism came to little obvious harm when left untreated.
Primary hyperparathyroidism is increasingly recognised as a common disorder. Some 60 000 new cases occur each year in the United States,20 and in Britain the widespread use of routine serum calcium assays might yield 13 000 new cases yearly. 21 Were parathyroid exploration regarded as mandatory the cost would be large22 and some morbidity and mortality would be inevitable.
Patients with symptoms such as renal calculi, peptic ulceration, pancreatitis, or fractures should certainly be advised to have a parathyroidectomy. It is more difficult to assess the relevance of non-specific symptoms such as depression and lassitude as indications for surgery. Some patients undoubtedly benefit2 15; in others the operation may serve as a powerful placebo. 23 Hypertension is more common in hyperparathyroid subjects than in age matched controls22 but is seldom relieved by a successful parathyroidectomy and cannot by itself be regarded as an indication for surgery."
Indications for parathyroid surgery in apparently symptomless patients remain controversial. It is clear from our study that, untreated, such patients do not necessarily have progressive renal damage and seldom develop skeletal problems or acute hypercalcaemia. Conservative management is not an unreasonable option and patients without symptoms need not be bullied into having surgery.
We are indebted to Professor G H Bell for comments on the text and to Mr N S Brown for the parathyroid hormone assays.
thyroidism. Aust NZJ Med 1979;9:17-23.
(Accepted 29 Augnst 1984) Loperamide in acute diarrhoea in childhood: results of a double blind, placebo controlled multicentre clinical trial DIARRHOEAL DISEASES STUDY GROUP (UK) Abstract A total of 315 young children with acute diarrhoea were included in a double blind, hospital based multicentre trial of loperamide at two dose levels (0 8 mg and 0-4 mg/ kg/24 h), given with standard oral rehydration therapy versus placebo plus oral rehydration therapy. The overall recovery rate was slowest in the placebo group and fastest in the group given loperamide 0 8 mg. Com-Introduction Glucose-electrolyte solutions are highly effective in treating dehydration in acute diarrhoea by stimulating glucose coupled sodium transport in the small intestine.1 2 The use of adjunct therapy in oral rehydration remains controversial, but agents that effectively inhibit the net secretion of fluid and electrolytes by the intestine without serious side effects may have a place.
Naturally occurring opioids have been used as antidiarrhoeal agents since antiquity but their central effects make them undesirable. Loperamide, a recently developed opioid analogue, differs from other, similar drugs in that it binds predominantly to intestinal tissue and when given by mouth has virtually no access to the central nervous system.3 Its antidiarrhoeal action was thouglt to result exclusively from diminished intestinal motility,5 but later studies showed loperamide to inbibit intestinal secretion induced by various bacterial enterotoxins.6 7 Clinical trials of loperamide in a dose of 0-2 mg/kg daily in the treatment of acute diarrhoea in young children have shown no significant advantage over placebo.8 9 Experience in the management of chronic secretory diarrhoea in childhood, however, indicates that therapeutic response is dose related and that higher doses of loperamide are well tolerated by young children.'0 A double blind, hospital based multicentre trial was therefore undertaken to compare loperamide at two high doses (0 4 mg and 0 8 mg/kg/24 h) given with standard oral rehydration therapy against placebo given with oral rehydration therapy in young children with acute diarrhoea.
Design of trial RECRUITMENT AND PATIENTS STUDIED
The study was conducted in four centres in England: the Leeds Road Hospital, Bradford; the Royal Alexandra Hospital for Sick Children, Brighton; Alder Hey Children's Hospital, Liverpool; and the Queen Elizabeth Hospital for Children, London. At least 60 patients were to be recruited at each centre.
Eligible patients were children aged 3 months to 3 years who were admitted to hospital with a diagnosis of acute diarrhoea of less than two weeks' duration. Patients excluded were (a) those with specific malabsorption syndromes such as coeliac disease, (b) those in whom diarrhoea was an incidental problem complicating some other acute disease, and (c) those who had been given loperamide or diphenoxylate during the 24 hours before admission.
TREATMENT REGIMENS The three treatment regimens compared were (a) rehydration plus loperamide syrup 0 8 mg/kg body weight daily; (b) rehydration plus loperamide syrup 0 4 mg/kg body weight daily; and (c) rehydration plus placebo syrup (matched vehicle). Trial drugs were prepared by Janssen Pharmaceutical Limited in identical bottles and packed in sets of 60 for distribution to the centres. Each set consisted of equal numbers of bottles containing 100 ml of each of the three trial preparations, the order having been determined using random numbers. The bottles were labelled with serial patient study numbers. A sealed code was provided to the hospital pharmacist at each of the centres and copies kept by Janssen Pharmaceutical Limited and the statistics unit of the department of tropical paediatrics at the Liverpool School of Tropical Medicine.
PROCEDURE AND MANAGEMENT OF PATIENTS
On recruitment to the study each patient was entered in a tria register, given the next available patient trial number, and allocated the bottle of syrup corresponding to that number, together with a set of study forms.
The start of the study period was defined as the time of administration of the initial dose of the trial drug. If the initial dose was administered less than six hours before the scheduled time for routine ward drug administration the second dose was not given until the routine administration 12 intravenous fluids as appropriate. Oral glucose-electrolyte mixture was introduced as soon as could be tolerated. Regrading on to normal feeds was accomplished according to the routine of each centre. ASSESSMENT 
CRITERIA
The time that diarrhoea was deemed to have resolved was determined as follows: (a) At the passage of the first formed stool diarrhoea was considered to have stopped at the time of the last unformed stool. (b) At the passage of the second semisolid stool diarrhoea was considered to have stopped at the time of the first semisolid stool. (c) When no stools had passed for 24 hours diarrhoea was considered to have stopped at the time of the last unformed stool. The duration of diarrhoea was defined as the time from first dose of the trial drug to resolution of diarrhoea.
Weight change was defined as the difference between the weight on admission (day 1) and the weight recorded on day 3. If the last weight recorded was on day 2, this was used instead of the weight on day 3.
Careful watch was kept for any adverse effects, particularly abdominal distension, paralytic ileus, and depression of the central nervous system. In the event of any adverse reaction the doctor responsible for the study at the centre made a decision about the need to change treatment.
LABORATORY METHODS
Laboratory procedures for estimating serum electrolyte values and detecting pathogens in stools were those currently in routine use in each centre.
MANAGEMENT OF DATA
The study forms for each patient comprised a general form, follow up chart, and stool chart. The general form recorded time and date of recruitment, date of birth, sex, duration of diarrhoea, state of dehydration (nil, <5°,,, 5-10 0, >100'), serum electrolyte (Nat, Kt, Cl-, HCO,) and urea concentrations, stool pathogens isolated on admission, and drugs given before admission and during the study. The There were several deviations from the specified treatment regimen, including variations in dosage and timing of drug administration. Four patients were discharged before diarrhoea had resolved. These were included in the analysis with diarrhoea unresolved until day of discharge. Table I gives the background data on the patients in the three treatment groups. The only discrepancy noted among the groups was in the proportions from whom pathogens were isolated-270'0 of the group given 0 8 mg loperamide, 41 0( of the group given 0-4 mg loperamide, and 44oe of the placebo treated group. Serum electrolyte and urea values were similar in the three groups. 10 NOVEMBER 1984 strata. The presence or absence of pathogens was the only variable that appeared to influence recovery rates. Table IV lists the types of pathogens isolated. The overall relative recovery rate for patients with no pathogens in their stools was 1 13 compared with 0 90 for those with viruses and 0 71 for those with bacteria. When relative recovery rates were calculated for the three treatment groups with patients stratified by stool pathogens (and centre) the rates for the loperamide groups were higher than for placebo but the differences were no longer significant. The numbers of patients whose weight had increased by day 3 after admission were determined for each of the treatment groups.
The proportions were 58% in the 0 8 mg loperamide group, 51% in the 0-4 mg loperamide group, and 36% in the placebo group. These differences were significant (X2=8-36; 2 df; p<002).
Discussion
The widespread introduction of oral rehydration therapy had a major impact on the treatment of diarrhoeal diseases in childhood. In 1978 a leading article in the Lancet suggested that an understanding of the physiology of Na+ coupled glucose absorption that gave impetus to oral rehydration therapy was perhaps the most important medical advance this century.12 Nevertheless, despite this important contribution to treatment acute diarrhoea remains a cause of considerable morbidity and appreciable mortality, mainly in developing but also in developed countries of the world.
The role of pharmacological agents in the treatment of diarrhoea is less clear; though several are effective, their side effects are unacceptable. The piperidine opioid loperamide, which has effective antidiarrhoeal properties and few side effects, seemed to merit consideration as an adjunct to oral rehydration therapy. Studies at the currently recommended dosage of 0 2 mg/kg daily showed no clear effects.8 0 Sandhu et al found that children with protracted diarrhoea in whom the intestine is in a secretory state with respect to water and electrolytes respond well to doses of loperamide up to 3-8 mg/kg daily.'0 In view of this, doses twice (0 4 mg/kg) and four times (0-8 mg/ kg) the recommended dose were tested.
In our series more pathogens were isolated from the placebo group than from the group given 0-8 mg loperamide per kg (table I). The difference was greater than could be explained by chance using random allocation of treatments. The explanation probably relates to the procedures used for detecting pathogens. Patients who passed no stool after entry to the trial (designated BNO) had a chance of having pathogens isolated only if a pre-entry stool was collected or if other means were used to recover a sample before discharge. Conversely, patients with prolonged diarrhoea sometimes had several stools sent for analysis and thus had a higher chance of having pathogens isolated. The loperamide groups contained a higher proportion of designated BNO than the placebo group. It is therefore debatable whether the analysis of recovery rates should have been extended to include stratification of patients by stool pathogens, since this probably results in a stratification by duration of diarrhoea.
Our results show that the duration of the diarrhoea was shortened in those patients given loperamide in addition to standard oral rehydration therapy. In particular, 0-8 mg loperamide speeded recovery by about 24 hours.
A time honoured argument against the use of antimotility drugs in acute diarrhoea rests on the premise that reduced motility and stasis favour multiplication of pathogens and is potentially harmful. There was no evidence in this study to suggest such deleterious effects associated with the use of loperamide. No serious side effects of loperamide were observed.
The drug was withdrawn in one child because of abdominal distention, which was present before the administration of loperamide and was associated with pneumonia.
Acute diarrhoea is usually a self limiting illness in well nourished children, provided that fluid and electrolyte losses are adequately replaced. Hence the use of drugs to control diarrhoea is generally regarded as unnecessary, uneconomic, and potentially unsafe.
Loperamide, in the dosage employed in this study, reduced the duration of diarrhoea, enhanced weight gain with oral rehydration, and was non-toxic. We therefore conclude that loperamide is a safe and potentially useful adjunct to oral rehydration in well nourished children with acute diarrhoea.
We emphasise, however, that while loperamide may be a useful adjunct to oral rehydration therapy, it cannot be used as a substitute; nor should it be regarded as a routine adjunct to treatment. Loperamide may prove useful in the management of acute diarrhoea when response to oral rehydration alone is slow or unsatisfactory.
Extrapolation from this study to malnourished populations in developing countries is unwarranted and must be discouraged. Similarly designed trials are in progress abroad and will be reported. SHORT REPORTS Shrinkage of a uterine fibroid after subcutaneous infusion of a LHRH agonist Fibroids (leiomyomas) are the commonest tumours of the uterus. These smooth muscle neoplasms contain more high affinity oestrogen receptors than neighbouring normal uterine muscle' and depend on oestrogen for growth. Oestrogen dependence of fibroids is further reflected in their degeneration and atrophy after the menopause. This suggests that induction of a hypo-oestrogenic state in patients with uterine fibroids would cause shrinkage of these tumours.
Suppression of the pituitary-gonadal axis can be achieved by long term administration of agonist analogues of luteinising hormone releasing hormone (LHRH), and this approach offers the potential for treatment of certain gynaecological disorders.2 Treatment with a LHRH agonist by injection or nasal spray is typically started in the early follicular phase of the menstrual cycle. This initially stimulates, rather than inhibits, oestrogen secretion without attendant progesterone secretion. That is clearly undesirable when suppression of ovarian function is sought. A study by one of us (HMF) in non-human primates showed that infusion of a LHRH agonist from day 21, rather than days 1-3, of the menstrual cycle produced more consistent, rapid, and profound suppression of plasma oestradiol. We report here on a woman whose symptomatic uterine fibroids shrank over several weeks during administration of a LHRH agonist by subcutaneous infusion from day 21 of the cycle.
Case report A 21 year old nulligravid woman presented after two years of intractable dysmenorrhoea. She had been prescribed courses of high dose aspirin, combined oral contraceptives, and mefenamic acid without benefit. A diagnostic laparoscopy was undertaken. On examination under anaesthesia a mass about 5 cm in diameter was palpable to the right of the uterine fundus; the internal uterine cavity was regular, excluding a bicornuate uterus. At laparoscopy the mass was seen to be a uterine fibroid at the right uterotubal junction. Hysterosalpingography showed that the fibroid distorted the filling pattern of the right uterine tube. Fibroid myomectomy was contraindicated because of the site of the tumour with the attendant risk of tubal damage and subsequent infertility.
A trial of treatment with a LHRH agonist (D-Ser(BU')6LHRH (1) (2) (3) (4) (5) (6) (7) (8) (9) ethylamide; buserelin; Hoechst Pharmaceuticals) was offered in an attempt to lower ovarian oestrogen secretion and reverse the oestrogen dependent fibroid growth. We decided to use a subcutaneous infusion of the LHRH agonist via a preprogrammed miniaturised automatic pump (90 X 50 x 25 mm; National Institute for Medical Research, Mill Hill)3 in an attempt to deliver near continuous LHRH agonist to the pituitary. The 
Comment
Fibroids are the commonest indication for hysterectomy: in Britain in 1979, 15 600 hysterectomies for fibroids were performed (S Cole, personal communication). Typically the patient with symptomatic fibroids is approaching her climacteric, and a course of LHRH agonist may not only eliminate pain or bleeding or both in these women but also, by controlling tumour growth until the natural menopause, remove the need for hysterectomy. Possibly, LHRH agonist treatment of fibroids will, by reducing growth and their blood supply, result in cystic degeneration or necrosis or even lead to spontaneous resolution. Such an effect on the clinical course of these tumours in the younger or infertile patients might render fibroid myomectomy unnecessary or allow a more minor operation, such as carbon dioxide laser coagulation of the remaining focus of the fibroid at laparoscopy. 4 Administration of a LHRH agonist to this patient resulted in a 5000 decrease in fibroid volume within a month. Starting treatment from day 21 of the menstrual cycle avoided the initial unopposed increase in plasma oestradiol concentrations that occurs when the agonist is begun in the follicular phase. Use of an automatic pump to deliver the drug in a near continuous fashion produced a rapid suppression of ovarian function and low plasma oestradiol concentrations. Apart from the expected menstruation, no other vaginal bleeding was observed in our patient, unlike in another study of administration of a LHRH agonist to a patient with fibroids.5 This delivery system appears promising as a means of consistently suppressing ovarian function in oestrogen dependent gynaecological diseases. We expect that, should long term LHRH agonist treatment of fibroids prove clinically useful in large series of patients, it should be possible to use slow release subcutaneous implants of these drugs, which are currently being developed by pharmaceutical companies, so removing the need for a mechanical pump.
We are grateful to Professor D T Baird, Dr J Sandow, Dr P Magill, Sister A Cook, and Miss M Abbott for their help with this study. DLH is a Wellcome Trust senior clinical research fellow.
